* Pull-down experiments indicated that PEGylation of PRX-102 masks certain epitopes, which likely contributes to the reduced ADA affinity and a notable decrease in inhibitory effects on PRX-102.
* Our findings suggest that switching from traditional treatments to PRX-102 could be beneficial for patients with pre-existing ADAs, and this transition is currently being tested in clinical trials